ArticleESC heart failure2024

Empagliflozin cost-effectiveness analysis in Japanese heart failure with mildly reduced and preserved ejection fraction.

Hiroyuki Tsutsui et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.